Research Article Details
| Article ID: | A52563 |
| PMID: | 25592279 |
| Source: | Mol Biosyst |
| Title: | Dissection of metabolic pathways in the Db/Db mouse model by integrative proteome and acetylome analysis. |
| Abstract: | Insulin resistance is often associated with excessive caloric intake and metabolic syndrome (MS) favours the development of Diabetes Mellitus Type II (T2DM). T2DM is a chronic disease with severe long-term consequences, such as dyslipidemia, retinopathy, kidney failure, and cardiovascular diseases. Although studied extensively, several aspects of T2DM remain poorly understood. Liver is the leading organ in the maintenance of metabolic fitness serving as the first relay station for processing dietary information in a direct response to nutritional input and changes in insulin and other endocrine signals. Evidence from several murine models suggests a unique function of the liver in the development of MS and T2DM. Here, we utilised Db/Db mice to understand the impact of T2DM on the proteome of liver cells. Global analysis of the liver proteome using a SILAC approach identified 407 significantly regulated proteins under diabetic conditions out of 8500 identified liver proteins. Furthermore, we mapped 1604 different acetylation sites in liver proteins. After normalization of the protein level, we identified 34 regulated acetyl lysine residues on 21 individual proteins, which were significantly altered in Db/Db compared to wild-type livers. We reason that the dataset provides a versatile resource for functional studies aiming to understand consequences of changes in protein abundances and acetylation in livers of diabetic animals. |
| DOI: | 10.1039/c4mb00490f |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |